Pasithea Therapeutics Stock (NASDAQ:KTTA)

Ownership Financials Chart

Previous Close

$1.60

52W Range

$0.92 - $7.69

50D Avg

$1.37

200D Avg

$3.38

Market Cap

$3.84M

Avg Vol (3M)

$2.75M

Beta

0.59

Div Yield

-

KTTA Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Sep 15, 2021

Website

KTTA Performance

KTTA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	$486.56K
Operating Income	$-14.25B	$-15.98M	$-14.82M
Net Income	$-13.90B	$-15.96M	$-13.06M
EBITDA	$-14.25B	$-15.33M	$-12.58M
Basic EPS	$-12.69K	$-12.65	$-10.34
Diluted EPS	$-12.69K	$-13.01	$-10.34

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
KZR	Kezar Life Sciences, Inc.
ABVC	ABVC BioPharma, Inc.
MNOV	MediciNova, Inc.
KRON	Kronos Bio, Inc.
KPRX	Kiora Pharmaceuticals, Inc.
VRAX	Virax Biolabs Group Limited
REVB	Revelation Biosciences, Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
INDP	Indaptus Therapeutics, Inc.
RNXT	RenovoRx, Inc.
FBRX	Forte Biosciences, Inc.